Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: another session of sorrow

September 29, 2019 10:00am

The downside definitely had the advantage with 13 out of the 27 downside with higher than the 3 month average volume while only 4 out of the 14 upside had higher than the 3 month average volume;

As the wall of worry heightens with three (3) negative closes ending the week

Q3 ends on Monday and September’s rocky road

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

The Dow closed down -70.87 (-0.26%), the S&P closed down -15.83 (-0.53%) and the NASDAQ closed down -91.03 (-1.13)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Friday the IBB closed down -0.78% while the XBI closed down -0.59%
Thursday the IBB closed down -2.05% while the XBI also closed down -2.16%
Wednesday the IBB closed down -0.75% while the XBI also closed down -0.78%

Henry’omics:

Sector equities and markets finished the week lower after reports that the White House is considering limits on U.S. investment into China, aggravating the protracted trade dispute between the globe’s two largest economies.

The S&P 500 (-1%), Dow (-0.4%) and NASDAQ (-2.1%) all notched week-to-date losses. The decline in all three major indexes for the week follows the prior week’s decline.

U.S. consumer spending slowed more than expected in August, according to a government report released Friday. Personal consumption expenditures, also known as household spending, edged up an adjusted 0.1% in August from July, when spending rose 0.5%. The print represents consumer spending’s softest read since February and could suggest to policymakers that a critical driver of U.S. GDP growth is decelerating. Consumer spending accounts for more than 66% of total economic output in the United States <CNBC>.

Q3 ends … Monday … woe the thoughts of upside as reporting swings into action!

The advance/decline line scenario of 45 covered companies:

Friday the close was negative with an A/D line of 14/27, 2 flats and 2 acquired;
Thursday the close was negative with an A/D line of 9/32 and 2 flats and 2 acquired;
Wednesday the close was negative with an Advance/Decline (A/D) line of 16/26, 1 flat and 2 acquired;

Decliners:

bluebird bio (BLUE -$3.02 after Thursday’s +$9.29);
BioMarin Pharmaceuticals (BMRN -$2.91);
Global Blood Therapeutics (GBT -$2.05 after Thursday’s -$2.93);
uniQure (QURE -$1.67 after Thursday’s -$2.80);
AxoGen (AXGN -$1.66);

Incliners:

ReNeuron (RENE.L +$17.50 after Thursday’s +$15.00);
Alnylam Pharmaceuticals (ALNY +$1.04 after Thursday’s -$2.33);
Voyager therapeutics (VYGR +$0.54);
Cesca Therapeutics (KOOL +$0.53);
Spark Therapeutics (ONCE +$0.43);

The percentage (%) indicators:

Friday’s range of the 14 upside was +0.12% (RGNX) to +8.14% (RENE.L) while the 27 downside ranged from -0.30% (BOLD) to -30.65% (HSGX);
Thursday’s range of the 9 upside was +1.13% (CLBS) to +7.50% (RENE.L) while the 32 downside ranged from -0.% (N/A) to -% (N/A);
Wednesday’s range of the 16 upside was +0.11% (IONS) to +7.73% (HSGX) while the 26 downside ranged from -0.30% (SGMO) to -3.85% (VSTM);

Upside volume stats: to compare

Friday: 4 out of the 14 upside had higher than the 3 month average volume;
Thursday: 5 out of the 9 upside had higher than the 3 month average volume;
Wednesday: 4 out of the 16 upside had higher than the 3 month average volume;

Downside volume stats:

Friday: 13 out of the 27 downside had higher than the 3 month average volume;
Thursday: 12 out of the 32 downside had higher than the 3 month average volume;
Wednesday: 7 out of the 26 downside had higher than the 3 month average volume;

2 flat - CUR and MDXG with 2 acquired (AST and OSIR) - Spark Therapeutics (ONCE) acquision with Roche still on HOLD

September’s sessions:

Friday closed NEGATIVE with 27 decliners, 14 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 32 decliners, 9 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday – not reported

Monday – not reported

Friday closed NEGATIVE with xx decliners, xx advancers, x flat and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 31 decliners, 11 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 14 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 11 decliners, 32 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 17 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 18 decliners, 25 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 11 decliners, 31 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday was Labor Day

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

37 min ago
RMi pre-open: Check light

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.